SCHEMBL740988

SCHEMBL740988

CS(=O)(=O)N1CC2(CCN(C(=O)c3ccc4[nH]cnc4c3)CC2)c2ccccc21

nearest known ligand 0.58

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
HPGDS O60760 1/20 0.58
NPY5R Q15761 19/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL740490 0.83 HPGDS (0.55) HPGDSNPY5R
SCHEMBL738600 0.78 HPGDS (0.53) HPGDS
SCHEMBL761594 0.76 NPY5R (0.56) HPGDSNPY5R
SCHEMBL13646665 0.76 L3MBTL1 (0.61)
SCHEMBL14371431 0.75 NPY5R (0.51) HPGDSNPY5R
SCHEMBL14986299 0.74 NPY5R (0.67) NPY5R
SCHEMBL14973649 0.73 HPGDS (1.00) HPGDSNPY5R
SCHEMBL738652 0.73 MCHR2 (0.54)
SCHEMBL1063453 0.73 L3MBTL1 (0.57)
SCHEMBL740898 0.72 SMN1; SMN2 (0.48)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138342-B2 11β-hydroxysteroid dehydrogenase type 1 active spiro compounds High Point Pharmacueticals, LLC (US) 2012-03-20 US claimed
US-20090105289-A1 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds NOVO NORDISK A/S (DK) 2009-04-23 US claimed
EP-1802623-A1 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE SPIRO COMPOUNDS Novo Nordisk A/S (DK) 2007-07-04 EP claimed
WO-2006040329-A1 1 IBETA- HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE SPIRO COMPOUNDS NOVO NORDISK A/S (DK) 2006-04-20 WO claimed
US-8138342-B2 11β-hydroxysteroid dehydrogenase type 1 active spiro compounds High Point Pharmacueticals, LLC (US) 2012-03-20 US disclosed
US-8138342-B2 11β-hydroxysteroid dehydrogenase type 1 active spiro compounds High Point Pharmacueticals, LLC (US) 2012-03-20 US disclosed
US-8138342-B2 11β-hydroxysteroid dehydrogenase type 1 active spiro compounds High Point Pharmacueticals, LLC (US) 2012-03-20 US disclosed
US-20090105289-A1 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds NOVO NORDISK A/S (DK) 2009-04-23 US disclosed
US-20090105289-A1 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds NOVO NORDISK A/S (DK) 2009-04-23 US disclosed
US-20090105289-A1 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds NOVO NORDISK A/S (DK) 2009-04-23 US disclosed
EP-1802623-A1 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE SPIRO COMPOUNDS Novo Nordisk A/S (DK) 2007-07-04 EP disclosed
WO-2006040329-A1 1 IBETA- HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE SPIRO COMPOUNDS NOVO NORDISK A/S (DK) 2006-04-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105289-A1 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds HSD11B1, HSD3B1, HSD17B1 HPGDS 124/4885NPY5R 4444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.